abiraterone acetate sold brand name zytiga among others medication used treat prostate specifically used together corticosteroid metastatic castrationresistant prostate cancer mcrpc metastatic highrisk castrationsensitive prostate cancer either used following removal testicles along gonadotropinreleasing hormone gnrh taken common side effects include tiredness vomiting headache joint pain high blood pressure swelling low blood potassium high blood sugar hot flashes diarrhea severe side effects may include liver failure adrenocortical males whose partners become pregnant birth control supplied abiraterone acetate converted body abiraterone acetate works suppressing production androgens specifically inhibits thereby decreases production prevents effects hormones prostate abiraterone acetate described approved medical use united states european union world health organizations list essential available generic abiraterone acetate used combination prednisone corticosteroid treatment mcrpc previously called hormoneresistant hormonerefractory prostate form prostate cancer responding firstline androgen deprivation therapy treatment androgen receptor antagonists abiraterone acetate received food drug administration fda april european medicines agency ema september medicines healthcare products regulatory agency mhra september therapeutic goods administration tga march approval australia covered pharmaceutical benefits scheme used treat castrationresistant prostate cancer given combination prednisoneprednisolone subject conditions patient currently receiving chemotherapy either resistant intolerant docetaxel performance status disease since become progressive since treatment pbssubsidised abiraterone acetate abiraterone acetatemethylprednisolone sold brand name yonsa mpred composite package contains abiraterone acetate yonsa approved medical use australia march contraindications include hypersensitivity abiraterone acetate although documents state taken women may become medical reason woman take women pregnant even touch pills unless wearing cautions include severe baseline hepatic impairment mineralocorticoid excess cardiovascular disease including heart failure hypertension uncorrected hypokalemia adrenocorticoid side effects common frequency common frequency uncommon frequency rare frequency experience overdose abiraterone acetate specific antidote abiraterone acetate overdose treatment consist general supportive measures including monitoring cardiac liver abiraterone acetate substrate hence administered concurrently strong inhibitors ketoconazole itraconazole clarithromycin atazanavir nefazodone saquinavir telithromycin ritonavir indinavir nelfinavir voriconazole inducers phenytoin carbamazepine rifampin rifabutin rifapentine also inhibits likewise taken concurrently substrates enzymes narrow therapeutic spironolactone generally exerts antiandrogenic effects experimental evidence exists acts androgen receptor agonist androgendepleted environment capable inducing prostate cancer supported observations described several case abiraterone active metabolite abiraterone acetate inhibits manifests two enzymes halfmaximal inhibitory concentration nm nm approximately selective inhibition expressed testicular adrenal prostatic tumor tissues catalyzes two sequential reactions conversion pregnenolone progesterone derivatives activity b subsequent formation dehydroepiandrosterone dhea androstenedione respectively dhea androstenedione androgens precursors testosterone inhibition activity abiraterone acetate thus decreases circulating levels androgens dhea testosterone dihydrotestosterone dht abiraterone acetate via abiraterone capacity lower circulating testosterone levels less ngdl ie undetectable added concentrations considerably lower achieved castration alone addition abiraterone acetate castration found reduce levels dht dhea androstenedione relative castration accordance antiandrogenic action abiraterone acetate decreases weights prostate gland seminal vesicles abiraterone also acts partial antagonist androgen receptor ar inhibitor enzymes dehydrogenase steroid steroid eg addition abiraterone part activity drug found due potent active metabolite formed abiraterone inhibitor isomerase also found act competitive antagonist ar reportedly comparable potent antagonist however initial metabolite agonist ar promotes prostate cancer formation blocked coadministration dutasteride potent selective interest use abiraterone acetate treatment breast cancer due ability lower estrogen however abiraterone found act direct agonist estrogen receptor induces proliferation human breast cancer cells abiraterone acetate used treatment breast cancer combined estrogen receptor antagonist like spite antiandrogenic estrogenic properties abiraterone acetate appear produce gynecomastia side due inhibition glucocorticoid biosynthesis abiraterone acetate cause glucocorticoid deficiency mineralocorticoid excess associated adverse medication combined prednisone corticosteroid serves means glucocorticoid replacement prevents mineralocorticoid abiraterone acetate along galeterone identified inhibitor sulfotransferases involved sulfation dhea endogenous steroids compounds ki values submicromolar oral administration abiraterone acetate prodrug form commercial preparation converted active form abiraterone conversion likely esterasemediated cypmediated administration food increases absorption drug thus potential result increased highly variable exposures drug consumed empty stomach least one hour two hours food drug highly protein bound metabolized liver inactive metabolites drug excreted feces urine terminal halflife exception traditional dosing basis trial nccn added lowdose abiraterone food acceptable alternative standard dose treatment men prostate abiraterone acetate also known acetate synthetic androstane steroid derivative androstadienol endogenous androstane specifically derivative androstadienol pyridine ring attached position acetate ester attached hydroxyl abiraterone acetate acetate ester early mike jarman elaine barrie gerry potter cancer research uk centre cancer therapeutics institute cancer research london set develop drug treatments prostate cancer nonsteroidal androgen synthesis inhibitor ketoconazole model developed abiraterone acetate filing patent publishing first paper describing following rights commercialization drug assigned btg ukbased specialist healthcare company btg licensed product cougar biotechnology began development commercial cougar acquired johnson johnson developed sells commercial product conducting ongoing clinical trials expand clinical abiraterone acetate approved united states food drug administration april fda press release made reference phase iii clinical trial abiraterone acetate use associated median survival months versus months placebo study stopped early successful abiraterone acetate also licensed european medicines may national institute health clinical excellence nice recommend use drug within nhs costeffectiveness grounds position reversed manufacturer submitted revised use currently limited men already received one docetaxelcontaining chemotherapy subsequently approved treatment mcspc abiraterone inntooltip international nonproprietary name bantooltip british approved name abiraterone acetates major active metabolite abiraterone acetate usantooltip united states adopted name banmtooltip british approved name modified jantooltip japanese accepted name abiraterone also known developmental code names developmental code name abiraterone acetate marketed janssen biotech subsidiary johnson johnson brand name sun pharmaceutical brand name generic versions abiraterone acetate approved united generic versions yonsa available november may united states court appeals federal circuit upheld patent trial appeal board decision invalidating patent johnson johnson abiraterone intas pharmaceuticals markets drug brand name abiratas cadila pharmaceuticals markets drug abretone glenmark pharmaceuticals abiraprocitation needed marketed yonsa sun pharmaceutical industries licensed churchill abiraterone acetate marketed widely throughout world including united states canada united kingdom ireland elsewhere europe australia new zealand latin america asia generic version available india price month national centre pharmacoeconomics initially found abiraterone acetate cost effective based prices however following agreement supply lower price accepted generic zytiga version available india price month abiraterone acetate development treatment breast cancer ovarian cancer march phase ii clinical trials also investigation treatment congenital adrenal hyperplasia development reported potential people previously treated docetaxel survival increased months months versus months people castrationrefractory prostate cancer received chemotherapy received abiraterone acetate progressionfree survival months rather months placebo median followup period months overall survival better abiraterone abiraterone acetate may useful prevention testosterone flare initiation gnrh agonist therapy men prostate httpsenwikipediaorgwikiabirateroneacetate